Farhad Hafezi

About Farhad Hafezi

“A few years ago, our motivation began to be shaped by a growing sense that corneal cross-linking had reached a conceptual plateau. While the procedure had become widely adopted and proven effective at halting disease progression, its clinical logic remained constrained by rigid protocols, historical assumptions, and an overly narrow definition of success. We felt that the field was asking the wrong question – not simply whether we could stop ectasia, but whether we could do so more intelligently, more safely, and with greater benefit for patients’ visual function.

This prompted a shift in focus from protocol replication to mechanism-driven refinement. Through parallel basic science and clinical work, we began re-examining the photochemical foundations of cross-linking, particularly the roles of fluence, oxygen availability, epithelial modulation, and stromal thickness. The result has been a series of protocols designed not only to replace established standards but rather to expand the therapeutic envelope of CXL. High-fluence accelerated epithelium-off approaches demonstrated that treatment time could be substantially reduced without compromising the biomechanical effect. Advanced epithelium-on strategies challenged the assumption that epithelial removal is a prerequisite for efficacy. Second-generation individualized ELZA-sub400 concepts further showed that ultra-thin corneas needn't be excluded from effective treatment when endothelial safety is addressed through rational UV fluence delivery strategies.

In parallel, we became increasingly convinced that limiting cross-linking to disease stabilization alone underutilizes its potential. This led to a broader reconceptualization of CXL as a platform technology – one capable of contributing not only to biomechanical stabilization, but also to structured visual rehabilitation. Customized approaches such as ELZA-PACE, along with refinements in corneal allogenic intrastromal ring segment (CAIRS) implantation - in our case, ECO-CAIRS, reflect this evolution. The goal has not been to blur boundaries between procedures, but to integrate them coherently, guided by corneal phenotype rather than by dogma.

Looking ahead, the impact we aim for is not defined by any single protocol, but by a broader shift in how the field thinks about cross-linking: from a fixed procedure to a modifiable intervention, from uniform application to individualized strategy, and from stabilization alone toward meaningful visual rehabilitation. If successful, this evolution may help position CXL not as a mature endpoint, but as a still-developing foundation for not only halting ectatic corneas but rehabilitating them too.”